Article

Phenotypic and transcriptomic characterization of bicalutamide and enzalutamide resistance in castration-resistant prostate cancer cells

2025-06-02

Abstract excerpt

The cornerstone treatment for aggressive prostate cancer (PCa) is androgen deprivation therapy (ADT). Eventually PCa cells develop castration resistance, i.e. resistance to ADT. Castration resistant PCa initially responds to androgen signaling inhibitors such as bicalutamide and enzalutamide, but the cells become resistant to these drugs as well overtime. We used long-term cell cultures to create testosterone-depe...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 6415ba3a-4c1a-5124-bd29-9743ce162f41
DOI: 10.1101/2025.05.30.656961

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Phenotypic and transcriptomic characterization of bicalutamide and enzalutamide resistance in castration-resistant prostate cancer cellsDOI 10.1101/2025.05.30.656961Read

PHENOTYPIC CHARACTERIZATION OF TWO NOVEL CELL LINE MODELS OF CASTRATION RESISTANT PROSTATE CANCERSemantic proximity Read

Identification of genes required for enzalutamide resistance in castration-resistant prostate cancer cells <i>in vitro</i>Semantic proximity Read

Therapeutic Resistance Models and Treatment Sequencing in Advanced Prostate CancerSemantic proximity Read

Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide.Semantic proximity Read

Understanding the development of enzalutamide resistance based on a functional single-cell approachSemantic proximity Read

Phenotypic characterization of two novel cell line models of castration-resistant prostate cancer.Semantic proximity Read

Novel hormone therapies for advanced prostate cancer: Understanding and countering drug resistanceSemantic proximity Read

Gene expression signature of castrate resistant prostate cancerSemantic proximity Read

Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approachesSemantic proximity Read

Resistance to second generation antiandrogens in prostate cancer: pathways and mechanismsSemantic proximity Read

A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509Semantic proximity Read

Exploration and Identification of Potential Therapeutic Targets and Biomarkers for Docetaxel Resistant Prostate CancerSemantic proximity Read